Literature DB >> 16002503

Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm.

Mary Maluccio1, Anne M Covey, Ripal Gandhi, Mithat Gonen, George I Getrajdman, Lynn A Brody, Yuman Fong, William Jarnagin, Michael D'Angelica, Leslie Blumgart, Ronald DeMatteo, Karen T Brown.   

Abstract

PURPOSE: The vast majority of hepatocellular carcinomas (HCC) occur in patients with underlying liver dysfunction, making surgical resection available to only a subset of patients with adequate hepatic reserve. This study analyzes the authors' results with bland arterial embolization combined with radiofrequency ablation (RFA) or percutaneous ethanol injection (PEIT) compared with surgical resection for the treatment of solitary HCC up to 7 cm in size.
MATERIALS AND METHODS: A retrospective review of all patients undergoing either surgical resection or bland embolization combined with local ablation for solitary HCC between January 1996 and August 2002 was performed. Progression-free survival rate and overall survival rate were calculated by the Kaplan-Meier method.
RESULTS: There were 40 patients who underwent surgical resection and 33 patients who underwent embolization and ablation. Age, gender, and size of the treated lesion were not significantly different between the groups. The embolization/ablation group had more patients classified as Okuda stage II (P<.001). The surgical group had a longer median recurrence-free survival rate (53.1 vs 25.1 months). With a median follow-up of 23 months, the 1-, 3- and 5-year actuarial overall survival rates were 97%, 77%, and 56% for the embolization/ablation group and 81%, 70%, and 58% for the surgical group, respectively. There was no statistical difference in overall survival rates (P=.20).
CONCLUSIONS: Bland arterial embolization in combination with ablation is effective in treating solitary HCC lesions up to 7 cm and achieves similar overall survival rates to surgical resection in selected patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002503     DOI: 10.1097/01.RVI.0000161377.33557.20

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  22 in total

1.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 2.  HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.

Authors:  Thomas J Vogl; Tatjana Gruber-Rouh
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

3.  Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread.

Authors:  Julie N Leal; Mithat Gonen; Anne M Covey; Joseph P Erinjeri; George Getrajdman; Constantinos T Sofocleous; Michael D'Angelica; Ronald P DeMatteo; Ghassan K Abou-Alfa; William R Jarnagin; Yuman Fong; Karen T Brown
Journal:  J Vasc Interv Radiol       Date:  2015-05-30       Impact factor: 3.464

4.  Liver abscess following transarterial chemoembolization.

Authors:  Danny Cheng
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

Review 5.  Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma.

Authors:  Francesco Tovoli; Giulia Negrini; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2016-03-23

Review 6.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

7.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Thomas A Abrams; Steven R Alberts; Daniel Anaya Saenz; Chandrakanth Are; Daniel B Brown; Daniel T Chang; Anne M Covey; William Hawkins; Renuka Iyer; Rojymon Jacob; Andrea Karachristos; R Kate Kelley; Robin Kim; Manisha Palta; James O Park; Vaibhav Sahai; Tracey Schefter; Carl Schmidt; Jason K Sicklick; Gagandeep Singh; Davendra Sohal; Stacey Stein; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Andrew X Zhu; Karin G Hoffmann; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

8.  [Transarterial ablative therapy of hepatocellular carcinoma].

Authors:  A H Mahnken
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

Review 9.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

10.  Intermediate hepatocellular carcinoma: the role of transarterial therapy.

Authors:  Fabrizio Chegai; Antonio Orlacchio; Stefano Merolla; Serena Monti; Lorenzo Mannelli
Journal:  Hepat Oncol       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.